Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.45 |
| ▸ | GABRP | O00591 | 6/20 | 0.45 |
| ▸ | GABRD | O14764 | 6/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.45 |
| ▸ | GABRE | P78334 | 6/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.45 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.45 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2935704 | 0.86 | CYP1A2 (0.49) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL128612 | 0.84 | CYP1A2 (0.47) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL7008579 | 0.84 | CYP1A2 (0.47) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4443708 | 0.84 | CYP4F2 (0.50) | CYP4F2CYP4A11CYP1A2GABRA1GABRG2 | |
| SCHEMBL30542743 | 0.84 | CYP4F2 (0.50) | CYP4F2CYP4A11CYP1A2GABRA1GABRG2 | |
| Hydrochloric Acid SCHEMBL20357239 | 0.83 | CYP1A2 (0.46) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL9602508 | 0.83 | CYP4F2 (0.47) | CYP4F2CYP4A11CYP1A2GABRA1GABRG2 | |
| SCHEMBL2812756 | 0.81 | ALDH1A1 (0.56) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL743703 | 0.81 | CYP1A2 (0.44) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL127699 | 0.80 | CYP1A2 (0.53) | CYP1A2GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411361-B1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-8138189-B2 | Substituted benzene compounds as modulators of the glucocorticoid receptor | HOFFMAN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2411361-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2010108902-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1765811-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006002383-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| US-5691329-A | Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| US-5563158-A | CARDIOVASCULAR DISORDERS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| WO-1995018111-A1 | COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, CRHR1 | CYP4F2 238/4885CYP4A11 71/4885CYP1A2 209/4885 |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | ABCC3, HCCS, ABCC2 | CYP4F2 305/4885CYP4A11 2087/4885CYP1A2 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.